Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study
J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America)
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Session: ALERT: Infection in adults and children
Session type: Clinical trials session
Number: 4135
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Chalmers (Dundee, United Kingdom), C. Haworth (Cambridge, United Kingdom), M. Metersky (Farmington, United States of America), M. Loebinger (London, United Kingdom), F. Blasi (Milan, Italy), O. Sibila (Barcelona, Spain), A. O'Donnell (Washington DC, United States of America), E. Sullivan (Bridgewater, NJ, United States of America), K. Mange (Bridgewater, NJ, United States of America), C. Fernandez (Bridgewater, NJ, United States of America), J. Zou (Bridgewater, NJ, United States of America), C. Daley (Dundee (Angus), United States of America). Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study. 4135
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19 Source: Virtual Congress 2021 – Back to infection basics Year: 2021
Late Breaking Abstract - Characterization of hospitalized patients with Influenza: a retrospective study Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Late Breaking Abstract - Initiation of patient enrollment in treatment with BPaL in Ukraine: first intermediate results Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021
Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study Source: International Congress 2019 – Clinical approach to asthma management Year: 2019
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Automated coaching for physical activity in COPD patients: results from a pilot study Source: International Congress 2017 – Innovation in pulmonary rehabilitation and chronic care Year: 2017
Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B). Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021
Late Breaking Abstract - Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE) Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Late Breaking Abstract - Tocilizumab administration for the treatment of hospitalised patients with COVID-19: A systematic review and meta-analysis Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018